acetazolamide has been researched along with Familial Hypokalemic Periodic Paralysis in 21 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acetazolamide has been the most commonly used treatment for hypokalemic periodic paralysis since 1968." | 7.77 | Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. ( Davis, MB; Griggs, RC; Hanna, MG; Haworth, A; Ke, Q; Matthews, E; Portaro, S; Sud, R, 2011) |
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 7.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "Acetazolamide is a thiazide derivative clinically used in skeletal muscle disorders related to altered K+ homeostasis such as the periodic paralyses." | 5.31 | Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. ( Barbieri, M; Camerino, DC; Tricarico, D, 2000) |
| "A novel mutation in a family with hypokalemic periodic paralysis is described." | 5.31 | Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. ( Bendahhou, S; Cummins, TR; Fu, YH; Griggs, RC; Ptácek, LJ, 2001) |
| " In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria." | 4.84 | Treatment for periodic paralysis. ( Links, TP; Meola, G; Panzeri, M; Rose, MR; Sansone, V, 2008) |
| "Acetazolamide has been the most commonly used treatment for hypokalemic periodic paralysis since 1968." | 3.77 | Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. ( Davis, MB; Griggs, RC; Hanna, MG; Haworth, A; Ke, Q; Matthews, E; Portaro, S; Sud, R, 2011) |
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 3.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "Hypokalemic periodic paralysis is a neuromuscular disease characterized by a combination of flaccid paralysis episodes (or muscular weakness) that are related to low levels of potassium in blood." | 2.66 | [Hypokalemic periodic paralysis: a systematic review of published case reports]. ( Latorre, R; Purroy, F, 2020) |
| "Hypokalaemic periodic paralysis (hypoPP) is the archetypal skeletal muscle channelopathy caused by dysfunction of one of two sarcolemmal ion channels, either the sodium channel Nav1." | 2.46 | Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? ( Hanna, MG; Matthews, E, 2010) |
| "Hypokalemic periodic paralysis is a chronic condition characterized by sporadic attacks of weakness associated with acute hypokalemia." | 1.72 | The role of nephrologists in management of hypokalemic periodic paralysis: a case report. ( Li, J; Moten, S; Rauf, AA, 2022) |
| "Primary hypokalemic periodic paralysis is an autosomal dominant skeletal muscle channelopathy." | 1.42 | The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis. ( He, F; Huang, H; Jiang, Y; Ke, Q; Lu, L; Qi, M; Weng, C; Yi, X; Yu, P, 2015) |
| "We report a 14-year-old male with hypokalemic periodic paralysis." | 1.32 | [A case of hypokalemic periodic paralysis: utility of exercise test for the assessment of therapeutic efficacy]. ( Hasegawa, T; Itoyama, Y; Shiga, Y; Takeda, A; Watanabe, M, 2003) |
| "Interestingly, hypoPP is caused by both mutations affecting nearby codons as well as the change of an arginine into another amino acid." | 1.32 | New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. ( Eymard, B; Fontaine, B; Fournier, E; Hainque, B; Kuntzer, T; Laforet, P; Ochsner, F; Sternberg, D; Vicart, S, 2004) |
| "Acetazolamide is a thiazide derivative clinically used in skeletal muscle disorders related to altered K+ homeostasis such as the periodic paralyses." | 1.31 | Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. ( Barbieri, M; Camerino, DC; Tricarico, D, 2000) |
| "A novel mutation in a family with hypokalemic periodic paralysis is described." | 1.31 | Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. ( Bendahhou, S; Cummins, TR; Fu, YH; Griggs, RC; Ptácek, LJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Moten, S | 1 |
| Rauf, AA | 1 |
| Latorre, R | 1 |
| Purroy, F | 1 |
| Statland, JM | 1 |
| Fontaine, B | 3 |
| Hanna, MG | 3 |
| Johnson, NE | 1 |
| Kissel, JT | 1 |
| Sansone, VA | 1 |
| Shieh, PB | 1 |
| Tawil, RN | 1 |
| Trivedi, J | 1 |
| Cannon, SC | 2 |
| Griggs, RC | 3 |
| Tucker, C | 1 |
| Villanueva, L | 1 |
| Wu, F | 1 |
| Mi, W | 1 |
| Ke, Q | 2 |
| He, F | 1 |
| Lu, L | 1 |
| Yu, P | 1 |
| Jiang, Y | 1 |
| Weng, C | 1 |
| Huang, H | 1 |
| Yi, X | 1 |
| Qi, M | 1 |
| Matthews, E | 2 |
| Portaro, S | 1 |
| Sud, R | 1 |
| Haworth, A | 1 |
| Davis, MB | 1 |
| Ebus, S | 1 |
| Verrips, A | 1 |
| Ginjaar, IB | 1 |
| Verhagen, WI | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Kinoshita, M | 1 |
| Yabuki, D | 1 |
| Igarashi, O | 1 |
| Ichikawa, Y | 1 |
| Satoyoshi, E | 1 |
| Watanabe, M | 1 |
| Hasegawa, T | 1 |
| Takeda, A | 1 |
| Shiga, Y | 1 |
| Itoyama, Y | 1 |
| Links, TP | 2 |
| Ginjaar, HB | 1 |
| van der Hoeven, JH | 1 |
| Venance, SL | 1 |
| Jurkat-Rott, K | 1 |
| Lehmann-Horn, F | 1 |
| Tawil, R | 1 |
| Vicart, S | 1 |
| Sternberg, D | 1 |
| Fournier, E | 1 |
| Ochsner, F | 1 |
| Laforet, P | 1 |
| Kuntzer, T | 1 |
| Eymard, B | 1 |
| Hainque, B | 1 |
| Kim, JB | 1 |
| Lee, KY | 1 |
| Hur, JK | 1 |
| Ruff, RL | 1 |
| Sansone, V | 1 |
| Meola, G | 1 |
| Panzeri, M | 1 |
| Rose, MR | 1 |
| Tricarico, D | 1 |
| Barbieri, M | 1 |
| Camerino, DC | 1 |
| Nemoto, H | 1 |
| Kurihara, T | 1 |
| Bendahhou, S | 1 |
| Cummins, TR | 1 |
| Fu, YH | 1 |
| Ptácek, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol[NCT02582476] | Phase 2 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Terminated (stopped due to Slow enrolment and end of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for acetazolamide and Familial Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
[Hypokalemic periodic paralysis: a systematic review of published case reports].
Topics: Acetazolamide; Age of Onset; Calcium Channels, L-Type; Gene Frequency; Humans; Hypokalemic Periodic | 2020 |
Review of the Diagnosis and Treatment of Periodic Paralysis.
Topics: Acetazolamide; Andersen Syndrome; Anti-Arrhythmia Agents; Behavior Therapy; Carbonic Anhydrase Inhib | 2018 |
Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?
Topics: Acetazolamide; Animals; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Channelopathies; Humans; | 2010 |
[From gene to diseases; hypokalemic periodic paralysis].
Topics: Acetazolamide; Calcium Channels; Calcium Channels, L-Type; Carbonic Anhydrase Inhibitors; DNA Mutati | 2004 |
SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide.
Topics: Acetazolamide; Adult; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Humans; Hypokalemic | 2004 |
Treatment for periodic paralysis.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Dichlorphenamide; Humans; Hypokalemic Periodic Paralys | 2008 |
[Ion-channel related muscular diseases].
Topics: Acetazolamide; Anti-Arrhythmia Agents; Anticonvulsants; Carbamazepine; Humans; Hypokalemic Periodic | 1999 |
[Familial hypokalemic periodic paralysis].
Topics: Acetazolamide; Adenosine Triphosphate; Calcium Channels; Calcium Channels, L-Type; Carbonic Anhydras | 2001 |
13 other studies available for acetazolamide and Familial Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
The role of nephrologists in management of hypokalemic periodic paralysis: a case report.
Topics: Acetazolamide; Adult; Humans; Hypokalemia; Hypokalemic Periodic Paralysis; Male; Muscular Diseases; | 2022 |
Acute hypokalemic periodic paralysis possibly precipitated by albuterol.
Topics: Acetazolamide; Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol | 2013 |
Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
Topics: Acetazolamide; Animals; Arginine; Bumetanide; Calcium Channels, L-Type; Carbonic Anhydrase Inhibitor | 2013 |
The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis.
Topics: Acetazolamide; Adult; Asian People; Calcium Channels; Calcium Channels, L-Type; Female; Humans; Hypo | 2015 |
Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Cohort Studies; Female; Genetic Predisposition to Dise | 2011 |
Gastro-enteritis in hypokalemic periodic paralysis: a life threatening condition.
Topics: Acetazolamide; Adult; Anticonvulsants; Calcium Channels; Calcium Channels, L-Type; Diarrhea; Female; | 2012 |
Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis.
Topics: Acetazolamide; Acidosis, Renal Tubular; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Di | 2002 |
[A case of hypokalemic periodic paralysis: utility of exercise test for the assessment of therapeutic efficacy].
Topics: Acetazolamide; Administration, Oral; Adolescent; Anticonvulsants; Exercise Test; Humans; Hypokalemic | 2003 |
New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis.
Topics: Acetazolamide; Action Potentials; Adolescent; Adrenal Cortex Hormones; Adult; Amino Acid Substitutio | 2004 |
A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).
Topics: Acetazolamide; Adolescent; Arginine; Calcium Channels; Calcium Channels, L-Type; Codon; Exons; Famil | 2005 |
Sour on the inside, calm on the outside: how acetazolamide may stabilize membrane excitability.
Topics: Acetazolamide; Acids; Anticonvulsants; Humans; Hypokalemic Periodic Paralysis; Membrane Potentials; | 2006 |
Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis.
Topics: Acetazolamide; Animals; Homeostasis; Hypokalemic Periodic Paralysis; Male; Membrane Potentials; Musc | 2000 |
Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis.
Topics: Acetazolamide; Action Potentials; Adolescent; Adult; Carbonic Anhydrase Inhibitors; Cell Line; Femal | 2001 |